$2.410
+0.160 (+6.64%)At close
RADX News
RADX Events
Radiopharm Doses First Patient in Phase 1/2a Trial of RV-01
Radiopharm announced that it has dosed the first patient in the second cohort of its first-in-human Phase 1/2a clinical trial of RV-01 in patients with B7-H3 expressing tumors. This follows a positive recommendation from the Safety and Monitoring Committee, an independent multidisciplinary committee, to advance to the 70 mCi dose of RV-01.
Radiopharm Enters SPA to Issue 1.282M ADS with U.S. Investors
Radiopharm announced that it has entered into a securities purchase agreement, or SPA, with certain U.S. accredited institutional investors to issue, in a registered direct offering, 1.282M American depositary shares, representing 384.494M ordinary shares of the company, at an offering price of $3.16 per ADS, to raise aggregate gross proceeds of approximately $4.1M, before deducting the placement agent fees and other offering expenses payable by the company. In a concurrent private placement and pursuant to the terms of the SPA, the company has agreed to issue to the investors unregistered warrants to purchase up to 1.282M ADSs. The warrants will be exercisable on or after the effective date of shareholder approval of the issuance of the ordinary shares represented by ADSs issuable upon exercise of the warrants, will have an exercise price of $3.79 per ADS and will expire on July 31, 2029. The offering is expected to close on or about July 28, New York Time, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive U.S. placement agent for the offering.
Radiopharm Theranostics Presents New Data on 177Lu-RAD202 at AACR Meeting
Radiopharm Theranostics announced that new data from the ongoing Phase 0/1 HEAT trial, evaluating 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical therapy, will be presented as a poster at the American Association for Cancer Research, AACR, Annual Meeting 2026, being held April 17-22, 2026 in San Diego, California. Key Findings from the AACR Abstract and Poster: Meaningful tumor uptake of 177Lu-RAD202 was observed at the initial and lowest dose level of 30 mCi, particularly in breast cancer lesions; 177Lu-RAD202 was generally well tolerated in the first three treated patients, with predominantly Grade 1-2 treatment-emergent adverse events; No dose-limiting toxicities or treatment discontinuations due to adverse events were observed; Organ-level absorbed radiation doses were within expected and clinically acceptable ranges, supporting continued dose escalation
Radiopharm Advances 177Lu-RAD202 Clinical Trial to 130mCi
Radiopharm announced that it has received a recommendation from the Data Safety and Monitoring Committee, or DSMC, to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202, to the next dose level of 130mCi in the Phase 1 'HEAT' clinical trial in patients with Human Epidermal Growth Factor Receptor 2-positive advanced solid tumors. The DSMC is a multidisciplinary committee that conducts detailed reviews of study data, discusses potential safety events and provides recommendations regarding trial continuation.
Biotech Stocks Surge in Search Activity, Radiopharm Up 2566.66%
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:Radiopharm Theranostics, 2566.66% surge in interestSpruce Biosciences, 280.31% surge in interestSummit Therapeutics, 197.53% surge in interestPipeline and key clinical candidates for these companies:Radiopharmis a clinical stage radiotherapeutics company developing a "world-class platform of innovative radiopharmaceutical products" for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX and on NASDAQ. The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and four Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases.Spruce Biosciencesis a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need.Summit Therapeuticsis a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.Recent news on these stocks:March 27Summit Therapeutics announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2026 European Lung Cancer Congress in Copenhagen, Denmark. Three posters featuring updated ivonescimab data will be displayed on Friday, March 27 from 1:00 to 2:00 pm Central European Time. Data for HARMONi was generated and analyzed by Summit and for HARMONi-2 by our collaboration and licensing partner, Akeso. The first poster, "Intracranial Efficacy of Ivonescimab Plus Chemotherapy in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer in the HARMONi Study" includes outcome data from patients with and without asymptomatic brain metastases at baseline enrolled in HARMONi. These patients received either ivonescimab delivered in combination with chemotherapy, or chemotherapy alone in this global Phase III trial for patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with an EGFR TKI. Ivonescimab plus chemotherapy demonstrated an improvement in intracranial progression free survival in patients with baseline brain metastases of 10.1 months compared to 6.5 months for chemotherapy. In patients who did not have baseline CNS metastases, the addition of ivonescimab also showed an improvement in intracranial PFS over control arm with 15.7 months compared to 11.6 months. No new safety signals were identified across baseline brain metastasis subgroups. The second poster, "Health-Related Quality of Life in Patients Previously Treated with an EGFR-TKI from HARMONi: A Phase 3 Trial of Ivonescimab vs Placebo Plus Chemotherapy" includes data from patients enrolled in HARMONi. These patients received either ivonescimab delivered in combination with chemotherapy, or chemotherapy alone in this global Phase III trial for patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with an EGFR TKI. The third poster, "Health-Related Quality of Life with Ivonescimab Versus Pembrolizumab for PD-L1 Positive, NSCLC: a Randomised, Double-Blind, Phase 3 Study in China" includes data from patients enrolled in HARMONi-2 or AK112-303. These patients received either ivonescimab delivered as monotherapy, or pembrolizumab delivered as monotherapy in this Phase III study conducted exclusively in China for patients with locally advanced or metastatic NSCLC whose tumors have positive PD-L1 expression with all data collected and analyzed by Akeso.Hear more from InvestingChannel by signing up for.About "Biotech Alert"The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel's online financial news media ecosystem.This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.